Migraine Epidemiology, Diagnosis, and Preventive Gaps
Formal criteria for diagnosis.
Migraine Essentials is a resource for primary care physicians, PAs and NPs as well as consumers looking for authoritative insights into the diagnosis, treatment , and challenges of migraine disease.
Migraine Essentials are intended to be short and to the point text and audio content addressing a variety of issues in migraine disease not typically found in mainstream didactic CME, including the use of alternative treatments. Migraine Essentials is intended to compliment conventional CME, not replace it.
Butterbur Petasin serves as a rigorously tested, non-prescription preventive treatment for patients with episodic migraine.
Butterbur Petasin exerts multimodal effects across key migraine pathophysiologic pathways.
Butterbur Petasin significantly suppresses CGRP release in both the dura mater and trigeminal ganglion in a dose-dependent manner.
Butterbur Petasin significantly reduced migraine frequency from 3.4 to 1.8 attacks per month, compared with a smaller decrease from 2.9 to 2.6 in the placebo group.
Butterbur Petasin offers a clinically meaningful preventive option for adults with episodic migraine.
Seventy-seven percent achieved a ≥50% reduction in attack frequency, with an overall 63% reduction from baseline.
Butterbur Petasin demonstrated no clinically relevant hepatotoxicity, even with prolonged or high-dose exposure.
Exposure reached ~2.674 million patient-months worldwide, including ~2.04 million in US/Canada without any hepatobiliary AE reports in the latter region.
21 commercially available butterbur supplements were analyzed.
Two batch results by independent ISO 17025 laboratories
Butterbur Petasin is an evidence-based migraine preventive with a strong safety profile, contraindicated in pregnancy/lactation, liver disease, and Asteraceae allergies.